Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 17/20 | 0.49 |
| ▸ | MMP3 | P08254 | 17/20 | 0.49 |
| ▸ | MMP7 | P09237 | 16/20 | 0.49 |
| ▸ | MMP1 | P03956 | 14/20 | 0.48 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.48 |
| ▸ | MMP8 | P22894 | 2/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | MMP12 | P39900 | 1/20 | 0.48 |
| ▸ | MMP13 | P45452 | 1/20 | 0.48 |
| ▸ | MMP14 | P50281 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4425173 | 0.81 | MMP2 (0.69) | MMP2MMP3MMP7MMP1ADAM17 | |
| SCHEMBL7556923 | 0.78 | MMP2 (0.50) | MMP2MMP3MMP7MMP1ADAM17 | |
| SCHEMBL4425181 | 0.78 | MMP2 (0.74) | MMP2MMP3MMP7MMP1ADAM17 | |
| SCHEMBL6801588 | 0.77 | MMP2 (0.62) | MMP2MMP3MMP7MMP1ADAM17 | |
| SCHEMBL6808350 | 0.74 | MMP1 (0.54) | MMP2MMP3MMP1 | |
| SCHEMBL9714079 | 0.73 | ADAM17 (0.56) | MMP2MMP3MMP1ADAM17MMP8 | |
| SCHEMBL9713913 | 0.73 | ADAM17 (0.59) | MMP2MMP3MMP7MMP1ADAM17 | |
| SCHEMBL9714100 | 0.73 | ADAM17 (0.59) | MMP2MMP3MMP7MMP1ADAM17 | |
| SCHEMBL6799874 | 0.71 | MMP2 (0.62) | MMP2MMP3MMP7MMP1ADAM17 | |
| SCHEMBL6986265 | 0.71 | MMP2 (0.45) | MMP2MMP3MMP7MMP1ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6790834-B1 | Cytostatic agents | BRITISH BIOTECH PHARMACEUTICALS, LTD. (GB) | 2004-09-14 | — | — | US | disclosed |
| US-6462023-B1 | SUCH AS 2-HYDROXY-HYDROXYCARBAMOYL-METHYL)-4-METHYL-PENTANOYLAMINE)-2-PHENYL -ETHANOIC ACID CYCLOPENTYL ESTER; INHIBITING HYPERPROLIFERATIVE TUMOURGENIC CELLS SUCH AS MELANOMA AND/OR LYMPHOMA CELLS | BRITISH BIOTECH PHARMACEUTICALS, LTD. (GB) | 2002-10-08 | — | — | US | disclosed |
| EP-0925278-B1 | CYTOSTATIC HYDROXAMIC ACID DERIVATIVES | BRITISH BIOTECH PHARM (GB) | 2002-07-17 | — | — | EP | disclosed |
| US-6169075-B1 | ANTITUMOR AGENT INHIBITING THE PROLIFERATION OF A RANGE OF RAPIDLY DIVIDING TUMOUR CELLS LIKE MELANOMA AND/OR LYMPHOMA CELLS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2001-01-02 | — | — | US | disclosed |
| EP-0925278-A1 | CYTOSTATIC HYDROXAMIC ACID DERIVATIVES | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-06-30 | — | — | EP | disclosed |
| WO-1998011063-A1 | CYTOSTATIC HYDROXAMIC ACID DERIVATIVES | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1998-03-19 | — | — | WO | disclosed |